Please select the option that best describes you:
Following presentation of the PRINCE at ASCO 2016, should we be offering intermittent docetaxel to patients with metastatic castration-resistant prostate cancer?
At the ASCO 2016 annual meeting, results of the PRINCE trial were reported. A strategy of intermittent docetaxel was found to be non-inferior to continuous docetaxel in the treatment of castration-resistant prostate cancer. Given the statistical complexities of the trial, do you consider these results to be immediately practice-changing?
Answer from: Medical Oncologist at Academic Institution
The simple answer is no, as this study was dramatically underpowered to reach any conclusion. A couple of issues:1. This trial was designed after the TAX 327 data showed q3 week therapy to be the standard of care. This trial allowed weekly therapy anyway, likely because some of their docs wanted t...
Sign in or Register to read more